<!--[if gte mso 9]>

Normal
0


false
false
false







MicrosoftInternetExplorer4

<![endif]--><!--[if gte mso 9]>


<![endif]--><!--[if !supportAnnotations]--><!-- --><!--
function msoCommentShow(anchor_id, com_id)
{
if(msoBrowserCheck())
{
c = document.all(com_id);
a = document.all(anchor_id);
if (null != c && null == c.length && null != a && null == a.length)
{
var cw = c.offsetWidth;
var ch = c.offsetHeight;
var aw = a.offsetWidth;
var ah = a.offsetHeight;
var x = a.offsetLeft;
var y = a.offsetTop;
var el = a;
while (el.tagName != "BODY")
{
el = el.offsetParent;
x = x + el.offsetLeft;
y = y + el.offsetTop;
}
var bw = document.body.clientWidth;
var bh = document.body.clientHeight;
var bsl = document.body.scrollLeft;
var bst = document.body.scrollTop;
if (x + cw + ah / 2 > bw + bsl && x + aw - ah / 2 - cw >= bsl )
{ c.style.left = x + aw - ah / 2 - cw; }
else
{ c.style.left = x + ah / 2; }
if (y + ch + ah / 2 > bh + bst && y + ah / 2 - ch >= bst )
{ c.style.top = y + ah / 2 - ch; }
else
{ c.style.top = y + ah / 2; }
c.style.visibility = "visible";
} } }
function msoCommentHide(com_id)
{
if(msoBrowserCheck())
{
c = document.all(com_id);
if (null != c && null == c.length)
{
c.style.visibility = "hidden";
c.style.left = -1000;
c.style.top = -1000;
} }
}
function msoBrowserCheck()
{
ms = navigator.appVersion.indexOf("MSIE");
vers = navigator.appVersion.substring(ms + 5, ms + 6);
ie4 = (ms > 0) && (parseInt(vers) >= 4);
return ie4;
}
if (msoBrowserCheck())
{
document.styleSheets.dynCom.addRule(".msocomanchor","background: infobackground");
document.styleSheets.dynCom.addRule(".msocomoff","display: none");
document.styleSheets.dynCom.addRule(".msocomtxt","visibility: hidden");
document.styleSheets.dynCom.addRule(".msocomtxt","position: absolute");
document.styleSheets.dynCom.addRule(".msocomtxt","top: -1000");
document.styleSheets.dynCom.addRule(".msocomtxt","left: -1000");
document.styleSheets.dynCom.addRule(".msocomtxt","width: 33%");
document.styleSheets.dynCom.addRule(".msocomtxt","background: infobackground");
document.styleSheets.dynCom.addRule(".msocomtxt","color: infotext");
document.styleSheets.dynCom.addRule(".msocomtxt","border-top: 1pt solid threedlightshadow");
document.styleSheets.dynCom.addRule(".msocomtxt","border-right: 2pt solid threedshadow");
document.styleSheets.dynCom.addRule(".msocomtxt","border-bottom: 2pt solid threedshadow");
document.styleSheets.dynCom.addRule(".msocomtxt","border-left: 1pt solid threedlightshadow");
document.styleSheets.dynCom.addRule(".msocomtxt","padding: 3pt 3pt 3pt 3pt");
document.styleSheets.dynCom.addRule(".msocomtxt","z-index: 100");
}
// --><!--[endif]-->
<!--
/* Font Definitions */
@font-face
{font-family:PMingLiU;
panose-1:2 1 6 1 0 1 1 1 1 1;
mso-font-alt:&#26032;&#32048;&#26126;&#39636;;
mso-font-charset:136;
mso-generic-font-family:auto;
mso-font-format:other;
mso-font-pitch:variable;
mso-font-signature:1 134742016 16 0 1048576 0;}
@font-face
{font-family:"\@PMingLiU";
panose-1:0 0 0 0 0 0 0 0 0 0;
mso-font-charset:136;
mso-generic-font-family:auto;
mso-font-format:other;
mso-font-pitch:variable;
mso-font-signature:1 134742016 16 0 1048576 0;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{mso-style-parent:"";
margin:0cm;
margin-bottom:.0001pt;
mso-pagination:widow-orphan;
font-size:12.0pt;
font-family:"Times New Roman";
mso-fareast-font-family:PMingLiU;
mso-fareast-language:ZH-TW;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
{mso-style-noshow:yes;
margin:0cm;
margin-bottom:.0001pt;
mso-pagination:widow-orphan;
font-size:10.0pt;
font-family:"Times New Roman";
mso-fareast-font-family:PMingLiU;
mso-fareast-language:ZH-TW;}
span.MsoCommentReference
{mso-style-noshow:yes;
mso-ansi-font-size:8.0pt;
mso-bidi-font-size:8.0pt;}
@page Section1
{size:612.0pt 792.0pt;
margin:70.85pt 70.85pt 70.85pt 70.85pt;
mso-header-margin:36.0pt;
mso-footer-margin:36.0pt;
mso-paper-source:0;}
div.Section1
{page:Section1;}
-->
<!--[if gte mso 10]>

/* Style Definitions */
table.MsoNormalTable
{mso-style-name:"Table Normal";
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-parent:"";
mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
mso-para-margin:0cm;
mso-para-margin-bottom:.0001pt;
mso-pagination:widow-orphan;
font-size:10.0pt;
font-family:"Times New Roman";
mso-ansi-language:#0400;
mso-fareast-language:#0400;
mso-bidi-language:#0400;}

<![endif]-->In December 2006, after examining the available information collected on BZP (1-benzylpiperazine), the EMCDDA and Europol decided to launch a procedure for the production of a Joint report. Pursuant to the findings of this report, the Council of the EU formally requested a risk assessment <!--[if !supportAnnotations]--><!--[endif]-->&#160;of the substance, which was submitted to control measures and criminal penalties throughout the European Union in March 2008.<!--[if !supportAnnotations]--><!--[endif]-->

<!--[if gte mso 9]>

Normal
0


false
false
false







MicrosoftInternetExplorer4

<![endif]--><!--[if gte mso 9]>


<![endif]--><!--[if !supportAnnotations]--><!-- --><!--[endif]-->
<!--
/* Font Definitions */
@font-face
{font-family:PMingLiU;
panose-1:2 1 6 1 0 1 1 1 1 1;
mso-font-alt:&#26032;&#32048;&#26126;&#39636;;
mso-font-charset:136;
mso-generic-font-family:auto;
mso-font-format:other;
mso-font-pitch:variable;
mso-font-signature:1 134742016 16 0 1048576 0;}
@font-face
{font-family:"\@PMingLiU";
panose-1:0 0 0 0 0 0 0 0 0 0;
mso-font-charset:136;
mso-generic-font-family:auto;
mso-font-format:other;
mso-font-pitch:variable;
mso-font-signature:1 134742016 16 0 1048576 0;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{mso-style-parent:"";
margin:0cm;
margin-bottom:.0001pt;
mso-pagination:widow-orphan;
font-size:12.0pt;
font-family:"Times New Roman";
mso-fareast-font-family:PMingLiU;
mso-fareast-language:ZH-TW;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
{mso-style-noshow:yes;
margin:0cm;
margin-bottom:.0001pt;
mso-pagination:widow-orphan;
font-size:10.0pt;
font-family:"Times New Roman";
mso-fareast-font-family:PMingLiU;
mso-fareast-language:ZH-TW;}
span.MsoCommentReference
{mso-style-noshow:yes;
mso-ansi-font-size:8.0pt;
mso-bidi-font-size:8.0pt;}
@page Section1
{size:612.0pt 792.0pt;
margin:70.85pt 70.85pt 70.85pt 70.85pt;
mso-header-margin:36.0pt;
mso-footer-margin:36.0pt;
mso-paper-source:0;}
div.Section1
{page:Section1;}
-->
<!--[if gte mso 10]>

/* Style Definitions */
table.MsoNormalTable
{mso-style-name:"Table Normal";
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-parent:"";
mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
mso-para-margin:0cm;
mso-para-margin-bottom:.0001pt;
mso-pagination:widow-orphan;
font-size:10.0pt;
font-family:"Times New Roman";
mso-ansi-language:#0400;
mso-fareast-language:#0400;
mso-bidi-language:#0400;}

<![endif]-->In January 2010, increased evidence of the availability and use of mephedrone (4- methylmethcathinone) prompted the EMCDDA and Europol to launch a procedure for the production of a Joint Report. Pursuant to the findings of this report, the Council of the EU formally requested a risk assessment <!--[if !supportAnnotations]-->of the substance, which was submitted to control measures and criminal penalties throughout the European Union in December 2010.<!--[if !supportAnnotations]-->

&#160;

New prize for Europe's top scientific papers on drugs

Europe&#8217;s top scientific papers on drug-related topics will be acknowledged this year in a new award launched by the EMCDDA. The prize giving, to take place annually in Lisbon, will celebrate excellence in scientific writing in this area of critical concern to EU citizens. The inaugural event will take place in the margins of the EMCDDA Scientific Committee meeting, being held in the Portuguese capital from 14&#8211;15 November. Articles eligible for nomination for the award will focus on illicit drugs, although findings on licit substances may also be included. The articles will have been published in 2010 in peer-reviewed scientific journals, with the primary author based in an EU Member State or Norway. Entries may be submitted in any of the 23 languages of the European Union or in Norwegian, along with an abstract in English.

Drugnet Europe, the EMCDDA's quarterly newsletter, providesregular information on the Agency's activities to a broad readership.

In this issue: mephedrone ban across the EU; Poland passes new law to control &#8216;head shops&#8217; and &#8216;legal highs&#8217;; a new European Society for Prevention Research; 2011 EMCDDA work programme; a new prize for top scientific papers; new EMCDDA products and services.

The EMCDDA receives stable funding under Commission budget line B3-441 of the general budget of the European Union. Each year, a preliminary draft budget is presented by the Centre's Director to the Management Board, which may modify the draft before adopting it and submitting it to the European Commission. The Commission, in turn, makes its recommendations (which may again alter the draft) and presents the result to the European Council and Parliament.

<!--[if gte mso 9]>

Normal
0


false
false
false







MicrosoftInternetExplorer4

<![endif]--><!--[if gte mso 9]>


<![endif]-->
<!--
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{mso-style-parent:"";
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
mso-pagination:widow-orphan;
font-size:10.0pt;
mso-bidi-font-size:12.0pt;
font-family:Arial;
mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:"Times New Roman";
mso-fareast-language:EN-US;}
@page Section1
{size:612.0pt 792.0pt;
margin:70.85pt 3.0cm 70.85pt 3.0cm;
mso-header-margin:36.0pt;
mso-footer-margin:36.0pt;
mso-paper-source:0;}
div.Section1
{page:Section1;}
-->
<!--[if gte mso 10]>

/* Style Definitions */
table.MsoNormalTable
{mso-style-name:"Table Normal";
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-parent:"";
mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
mso-para-margin:0cm;
mso-para-margin-bottom:.0001pt;
mso-pagination:widow-orphan;
font-size:10.0pt;
font-family:"Times New Roman";
mso-ansi-language:#0400;
mso-fareast-language:#0400;
mso-bidi-language:#0400;}

<![endif]-->The 2011 work programme takes forward activities begun in 2010 to implement the EMCDDA&#8217;s three-year strategy (2010&#8211;12). Key themes of this strategy are the consolidation of core data, investment in more complex and policy-relevant analysis, and the development of a small number of new areas of strategic importance. Progress was made in all these areas in 2010, and this document details the next steps to be taken.

24.01.2011 EU agencies at the European Parliament

From Helsinki to Crete and from Lisbon to Vilnius, specialised agencies have been established to provide services, information, know-how and advice to the European Union, its Member States and citizens. At an upcoming exhibition at the European Parliament , 29 EU agencies will come together to explain what they do, why they exist and how they impact on the lives of Europe&#8217;s 500 million citizens.

Read more in the media annoucement >>

The main goal of the First European conference on drug supply indicators was to launch the work needed to establish a set of technically sound and sustainable indicators for monitoring drug markets, crime and supply reduction for Europe. The event brought together for the first time a wide range of European and international experts to assess the current state of the art in this domain and develop a realistic strategy for moving forward in an area of importance for European drug policies. The conference was a joint venture between the European Commission (EC) and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) with the active involvement of Europol.

The key conclusions from the event are presented in this document.

'Drug problems have no age limits' -- This special review published alongside the 2010 Annual report, reveals why drug use is no longer simply a &#8216;youth phenomenon&#8217;.Europe is experiencing a pronounced ageing of its population, around a quarter of which will be aged 65 or over by 2050. Statistics published today show that Europe&#8217;s drug-using population is also ageing and that meeting the needs of older drug users is a growing issue for treatment services. This is particularly the case in western countries which saw the EU&#8217;s first heroin epidemics in the 1980s and 1990s.

Focusing on European countries where amphetamine or methamphetamine is an important part of the drug problem, this Selected issue looks at the current situation in the light of the historical development of amphetamines use since the introduction of these substances as medicines in the 1930s. The history of amphetamines use is the result of an interplay of global forces, such as the spread of recreational drug use in the 1960s and the arrival of heroin on the European drug scene in the 1970s, and local events such as the rise of small-scale pervitin (methamphetamine) production in what was then Czechoslovakia. The outcome of this is that, in the present day, problem amphetamines use across Europe is marked by strong national characteristics, possibly more so than any other of the major illicit drugs.

A multilingual summary of the contents is available >>

Drugnet Europe, the EMCDDA's quarterly newsletter, providesregular information on the Agency's activities to a broad readership.

Inthis issue: EMCDDA releases Annual report 2010; Old realities, new threats and economic austerity; domestic cannabis cultivation widespread; amphetamines: a major problem in parts of Europe; Heroin problems &#8212; no sign of decline; Older drug users: a growing issue for Europe&#8217;s treatment services; EMCDDA and CICAD sign three-year work programme; new products and services.

The report on the state of the drugs problem in Europe presents the EMCDDA's yearly overview of the drug phenomenon. This is an essential reference book for policymakers, specialists and practitioners in the drugs field or indeed anyone seeking the latest findings on drugs in Europe. Published every autumn, the report contains non-confidential data supported by an extensive range of figures.

Drugnet Europe, the EMCDDA's quarterly newsletter, provides regular information on the Agency's activities to a broad readership.In this issue: 2010 work programme and budget; EMCDDA and Europol step up information collection on mephedrone; upcoming Guidelines for collecting data on retail drug prices in Europe; European drug prevention quality standards; EMCDDA signs accord with Ukrainian Ministry of Health; new Czech penal code enters into force; EMCDDA Management Board &#8211; changes at the helm; new products and services.

Drugnet Europe, the EMCDDA's quarterly newsletter, provides regular information on the Agency's activities to a broad readership.

In this issue: record number of new drugs in 2009; EMCDDA and ECDC assess anthrax outbreak among heroin users; global audit of HIV services for IDUs reveals low levels of provision; sharing information on drug treatment demand in the Mediterranean; drug use and pregnancy &#8212; challenges for public health; latest analysis of cocaine market highlights 'secondary extraction' laboratories in Europe; new products and services.

Drugnet Europe, the EMCDDA's quarterly newsletter, providesregular information on the Agency's activities to a broad readership.

In this issue: injecting drug use stable or declining; early-warning system annual meeting; EU scientific experts to assess risks of mephedrone; harm reduction moves to the mainstream; EMCDDA and EMA step up cooperation; European technical conference on drug supply indicators coming up; EMCDDA-CICAD cooperation; new products and services.

2010 Annual report launch

The report on the state of the drugs problem in Europe presents the EMCDDA's yearly overview of the drug phenomenon. This is an essential reference book for policymakers, specialists and practitioners in the drugs field or indeed anyone seeking the latest findings on drugs in Europe. Published every autumn, the report contains non-confidential data supported by an extensive range of figures.

Commissioned each year by the EMCCDA and produced by the national focal points of the Reitox network, the National reports draw an overall picture of the drug phenomenon at national level in each EU Member state. These data are key information to the EMCCDA and are an important resource, among others for the compilation of its 'Annual report'.

What are countries in Europe doing to prevent illicit drug use? The Prevention profiles section of the website tries to answer this question by providing information on the level of provision of different prevention measures in EU Member States, Croatia, Turkey and Norway.